SciFest is a science festival in Sweden, arranged by Uppsala University and the Swedish University of Agricultural Sciences (SLU). It offers a variety of scientific workshops, shows, competitions, research meetings, and lectures mainly dedicated to young people in schools and the public. This year, SciFest was held from the 4th until the 10th of March and provided numerous
Cline Scientific has entered into a collaboration with AstraZeneca to utilise Cline’s gradient technology as part of the multi-country European MSCA-ITN network, V.A Cure. V.A Cure is a Horizon 2020 funded project which aims to uncover core mechanisms of vascular anomalies and to leverage this information for establishing new therapeutics for vascular disease. The project
Due to Covid-19, European Research Night was organized as a series of virtual events all across Europe. Scientists prepared presentations with interaction with the audience, descriptive videos and live experiments. Five students from our network participated in these events. Martina De Bortoli and Murat Alpaslan from De Duve Institute prepared a video describing their research
The Human Molecular Genetics laboratory of the de Duve Institute (UCLouvain), headed by Professor Miikka Vikkula, has identified a novel gene responsible for a lymphatic disease called primary lymphedema. Together with the group of Professor Kari Alitalo in Finland, they identified mutations that alter the function of a protein that is known to play a
Lymphatic malformation is a debilitating and often incurable disease. Taija Mäkinen’s research group has in an international collaboration studied cellular mechanisms leading to abnormal vessel growth and identified a combination therapy that may allow effective treatment of these malformations. Lymphatic malformations are often congenital vascular anomalies that are characterised by abnormal vessel growth. These malformations
Finnadvance’s got funded for blood vessel-on-a-chip which could be used to treat rare vascular diseases! Organ- or body-on-chips both speed up the process and improve the safety and patient outcomes. Futuristic, but this can be a reality in 3-5 years! Official press release Finnadvance completes 550k€ seed round led by Voima Ventures and Finnish biotech
Diversity and environment that fosters equal opportunities in research are very important aspects of our project. Through inclusion of diversity, we grow professionally and personally.Early stage researchers of V.A.Cure project are coming from all over the world: Singapore, Iran, Vietnam, Turkey, Italy, Germany, Slovenia, Lebanon, Austria, Spain and USA.